This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Healthcare for Silver Years to Aid Encompass Health (EHC)
by Zacks Equity Research
Encompass Health's (EHC) inpatient rehabilitation and home hospice businesses are poised to grow on the back of aging population.
Encompass Health to Build Rehabilitation Hospital in Illinois
by Zacks Equity Research
Encompass Health (EHC) plans to build a rehabilitation facility in Illinois to serve the local community. The healthcare home will be launched in 2022 spring and complement other units in the area.
DGX vs. EHC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DGX vs. EHC: Which Stock Is the Better Value Option?
Encompass Health (EHC) Up 7.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health (EHC) Q1 Earnings Match Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 0.00% and -1.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Powerful Proof Anyone Can Invest for an Early Retirement - March 26, 2020
by Zacks Equity Research
Accomplishing the financial cushion to retire early is a fantasy for most, but bringing that fantasy to reality is not as difficult as it sounds. If you are willing to make some serious lifestyle adjustments, it can be achievable.
Signs That Your Trading Will Ruin Your Retirement - March 19, 2020
by Zacks Equity Research
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
Want To Retire Early? Learn the Intelligent Investing Secret - March 18, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Why Is Encompass Health (EHC) Down 3.2% Since Last Earnings Report?
by Zacks Equity Research
Encompass Health (EHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Encompass Health (EHC) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of -2.30% and -0.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Centene's (CNC) Q4 Earnings Miss Estimates, Improve Y/Y
by Zacks Equity Research
Centene's (CNC) fourth-quarter results gain traction from better revenues.
What's in the Cards for Centene's (CNC) Earnings in Q4?
by Zacks Equity Research
Centene's (CNC) Q4 earnings results are likely to reflect membership growth and better revenues.
Encompass Health (EHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Encompass Health (EHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investor Pick Encompass Health (EHC) Stock Now?
by Zacks Equity Research
Let's see if Encompass Health Corporation (EHC) stock is a good choice for value-oriented investors right now from multiple angles.
Why Encompass Health Corporation (EHC) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Encompass Health Corporation (EHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should Value Investors Buy Encompass Health (EHC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
EHC or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. USPH: Which Stock Is the Better Value Option?
Will Select Medical's Solid Run in 2019 Sustain in 2020?
by Zacks Equity Research
Acquisitions, partnerships and growth in admissions to drive Select Medical's (SEM) performance in 2020.
Encompass Health (EHC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 4.49% and 0.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Value Investors Consider Encompass Health (EHC) Stock?
by Zacks Equity Research
Encompass Health (EHC) stock may be a good choice for value-oriented investors right now from multiple angles.
Encompass Health (EHC) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 11.34% and 0.02%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EHC or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. USPH: Which Stock Is the Better Value Option?
Analysts Estimate Encompass Health (EHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Encompass Health (EHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Encompass Health (EHC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Encompass Health (EHC) delivered earnings and revenue surprises of 1.27% and 0.41%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?